Search - tctmd.com

Displaying 41 - 60 of 141

Sort: Relevancy | Date

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

News Conference News HRS 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

July 29, 2021

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

June 22, 2021

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

News Daily News

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

Yael L. Maxwell

April 09, 2021

Observational Study Supports Continuing Oral Anticoagulation During PCI

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

Statins in COVID-19: More Signs of Potential Benefit

News Daily News

Statins in COVID-19: More Signs of Potential Benefit

February 26, 2021

The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive

News Features

The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive

February 08, 2021

Checklist for Same-Day Discharge PCI Stresses Buy-In, and a Plan

News Daily News

Checklist for Same-Day Discharge PCI Stresses Buy-In, and a Plan

January 07, 2021

More Teamwork, Coordination Could Boost CV Studies in COVID-19

News Daily News

More Teamwork, Coordination Could Boost CV Studies in COVID-19

October 28, 2020

Study Affirms Thrombotic Risk in COVID-19

News Daily News

Study Affirms Thrombotic Risk in COVID-19

October 01, 2020

Aspirin Alone After TAVR Supported by Meta-analysis

News Daily News

Aspirin Alone After TAVR Supported by Meta-analysis

September 29, 2020

ABC-Bleeding Score Stratifies Risk in A-fib Patients on OAC and Aspirin

News Daily News

ABC-Bleeding Score Stratifies Risk in A-fib Patients on OAC and Aspirin

September 21, 2020

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

News Conference News ESC 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

September 04, 2020

Could Statins Curb Fatal or Severe COVID-19? Some Clues

News Daily News

Could Statins Curb Fatal or Severe COVID-19? Some Clues

Michael O'Riordan

August 14, 2020

NSAIDs Boost CV, Bleeding Risks in Post-MI Patients

News Daily News

NSAIDs Boost CV, Bleeding Risks in Post-MI Patients

July 28, 2020

PAD Patients Undertreated With Statins Despite Elevated CV Risk

News Daily News

PAD Patients Undertreated With Statins Despite Elevated CV Risk

July 13, 2020

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.